Interested to learn about how Orbis Medicines leverages our proprietary macrocycle technology? Our CTO Sevan Habeshian will be presenting a poster at TIDES USA 2024 in Boston. Stop by to learn more!
Om os
We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets.
- Websted
-
http://www.orbismedicines.com
Eksternt link til Orbis Medicines
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 2-10 medarbejdere
- Hovedkvarter
- Copenhagen
- Type
- Privat
Beliggenheder
Medarbejdere hos Orbis Medicines
Opdateringer
-
Today, we are thrilled to announce the official launch of Orbis Medicines alongside a €26 million financing. With our robust technology platform nGen, we can design orally bioavailable and membrane permeable macrocycle compounds – we think it’s a breakthrough and the start of a new era in #macrocycle #drugdevelopment after years of challenges in the design of macrocycle #medicines. We were founded by the Seeds Investment team of Novo Holdings based on the scientific work of Prof. Christian Heinis and Sevan Habeshian at the Swiss Federal Institute of Technology in Lausanne (École polytechnique fédérale de Lausanne). Alongside Novo Holdings, European life sciences investment leader Forbion co-led the financing. We look forward to transforming what is possible in the macrocycle space and ultimately delivering new therapeutic options to many #patients worldwide. You can learn more about Orbis in our press release: https://lnkd.in/eP6PbUPc #biotech
-